Rekvig OP, Putterman C, Casu C, et al. Autoantibodies in lupus: culprits or passive bystanders? Autoimmun Rev. 2012;11(8):596–603.
PubMed
Google Scholar
Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 2005;52(5):1481–90.
CAS
PubMed
Google Scholar
Pettersson T, Pukkala E, Teppo L, et al. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis. 1992;51(4):437–9.
CAS
PubMed
PubMed Central
Google Scholar
Björnådal L, Löfström B, Yin L, et al. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol. 2002;31(2):66–71.
PubMed
Google Scholar
Mellemkjaer L, Andersen V, Linet MS, et al. Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40(4):761–8.
CAS
PubMed
Google Scholar
Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130–5.
PubMed
PubMed Central
Google Scholar
Chen YJ, Chang YT, Wang CB, et al. Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Am J Med. 2010;123(12):1150.e1151–6.
Google Scholar
Moss KE, Ioannou Y, Sultan SM, et al. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis. 2002;61(5):409–13.
CAS
PubMed
PubMed Central
Google Scholar
Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15(9):577–83.
CAS
PubMed
Google Scholar
Bernatsky S, Ramsey-Goldman R, Clarke A. Exploring the links between systemic lupus erythematosus and cancer. Rheum Dis Clin North Am. 2005;31(2):387–402, viii-ix.
PubMed
Google Scholar
Imran A, Neelam F, Tariq M. Incidence of circulating antinuclear antibodies in cancer patients. Indian J Med Sci. 2003;57(3):113–6.
CAS
PubMed
Google Scholar
Zou HY, Gu X, Yu WZ, et al. Detection of serum antinuclear antibodies in lymphoma patients. Genet Mol Res. 2015;14(4):16546–52.
CAS
PubMed
Google Scholar
Torchilin VP, Iakoubov LZ, Estrov Z. Antinuclear autoantibodies as potential antineoplastic agents. Trends Immunol. 2001;22(8):424–7.
CAS
PubMed
Google Scholar
Lv S, Zhang J, Wu J, et al. Origin and anti-tumor effects of anti-dsDNA autoantibodies in cancer patients and tumor-bearing mice. Immunol Lett. 2005;99(2):217–27.
CAS
PubMed
Google Scholar
Syrigos KN, Charalambopoulos A, Pliarchopoulou K, et al. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. 2000;20:4351–3.
CAS
PubMed
Google Scholar
Mitchell P, Thatcher N, Socinski MA, et al. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol. 2015;26(6):1134–42.
CAS
PubMed
Google Scholar
Maire C, Vercambre-Darras S, Devos P, et al. Metastatic melanoma: spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohort. J Eur Acad Dermatol Venereol. 2013;27(1):92–6.
CAS
PubMed
Google Scholar
Bernatsky S, Joseph L, Boivin JF, et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis. 2008;67(1):74–9.
CAS
PubMed
Google Scholar
Bernatsky S, Ramsey-Goldman R, Joseph L, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014;73(1):138–42.
CAS
PubMed
Google Scholar
Löfström B, Backlin C, Sundström C, et al. A closer look at non-Hodgkin’s lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis. 2007;66(12):1627–32.
PubMed
PubMed Central
Google Scholar
Hsu CY, Lin MS, SuYJ, et al. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. Rheumatology (Oxford). 2017;56(4):620–8.
Google Scholar
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
CAS
PubMed
Google Scholar
Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35(6):630–40.
CAS
PubMed
Google Scholar
Singh G, Agarwal AK, Prosek J, et al. Can killers be saviors? Lupus. 2017;26(9):903–8.
CAS
PubMed
Google Scholar
Vlagea A, Falagan S, Gutiérrez-Gutiérrez G, et al. Antinuclear antibodies and cancer: a literature review. Crit Rev Oncol Hematol. 2018;127:42–9.
PubMed
Google Scholar
Dellen H, Seemayer NH. Autoimmunity in patients with bronchogenic carcinomas: occurrence of antibodies against nuclear antigens, chromosomes and ds-deoxyribonucleic acid. Zentralbl Bakteriol Mikrobiol Hyg B. 1983;177(6):451–68.
CAS
PubMed
Google Scholar
Attar SM, Koshak EA. Medical conditions associated with a positive anti-double-stranded deoxyribonucleic acid. Saudi Med J. 2010;31(7):781–7.
PubMed
Google Scholar
Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363–9.
CAS
PubMed
Google Scholar
Ibañez D, Urowitz MB, Gladman DD. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol. 2003;30(9):1977–82.
PubMed
Google Scholar
Gayed M, Bernatsky S, Ramsey-Goldman R, et al. Lupus and cancer. Lupus. 2009;18(6):479–85.
CAS
PubMed
Google Scholar
Klein A, Polliack A, Gafter-Gvili A. Systemic lupus erythematosus and lymphoma: incidence, pathogenesis and biology. Leuk Res. 2018;75:45–9.
CAS
PubMed
Google Scholar
Schmalzing M. The relationship of lymphoma and lupus-at least bidirectional. Rheumatology. 2019;58(7):1131–2.
PubMed
Google Scholar
Alarcón GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66(9):1168–72.
PubMed
PubMed Central
Google Scholar
Petri M, Purvey S, Fang H, et al. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum. 2012;64(12):4021–8.
CAS
PubMed
PubMed Central
Google Scholar
Ruiz-Irastorza G, Ugarte A, Egurbide MV, et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis. 2007;66(6):815–7.
CAS
PubMed
PubMed Central
Google Scholar
White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 2012;12(6):401–10.
CAS
PubMed
PubMed Central
Google Scholar
Sohn TA, Bansal R, Su GH, et al. High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. Carcinogenesis. 2002;23(6):949–57.
CAS
PubMed
Google Scholar
Sotelo J, Briceño E, López-González MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006;144(5):337–43.
CAS
PubMed
Google Scholar
Briceño E, Reyes S, Sotelo J. Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg Focus. 2003;14(2):e3.
PubMed
Google Scholar
Amaravadi RK, Lippincott-Schwartz J, Yin XM, et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res. 2011;17(4):654–66.
CAS
PubMed
PubMed Central
Google Scholar
Cook KL, Wärri A, Soto-Pantoja DR, et al. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. Clin Cancer Res. 2014;20(12):3222–32.
CAS
PubMed
PubMed Central
Google Scholar
Li J, Yang B, Zhou Q, et al. Autophagy promotes hepatocellular carcinoma cell invasion through activation of epithelial-mesenchymal transition. Carcinogenesis. 2013;34(6):1343–51.
CAS
PubMed
Google Scholar
Yang A, Kimmelman AC. Inhibition of autophagy attenuates pancreatic cancer growth independent of TP53/TRP53 status. Autophagy. 2014;10(9):1683–4.
CAS
PubMed
PubMed Central
Google Scholar
Helgason GV, Mukhopadhyay A, Karvela M, et al. Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy. Curr Cancer Drug Targets. 2013;13(7):724–34.
CAS
PubMed
Google Scholar
Pan Y, Gao Y, Chen L, et al. Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy. Clin Cancer Res. 2011;17(10):3248–58.
CAS
PubMed
Google Scholar
Yang ZJ, Chee CE, Huang S, et al. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther. 2011;10(9):1533–41.
CAS
PubMed
PubMed Central
Google Scholar
Wadström H, Arkema EV, Sjöwall C, et al. Cervical neoplasia in systemic lupus erythematosus: a nationwide study. Rheumatology (Oxford). 2017;56(4):613–9.
Google Scholar
Zard E, Arnaud L, Mathian A, et al. Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: a meta-analysis of the literature. Autoimmun Rev. 2014;13(7):730–5.
PubMed
Google Scholar
Tam LS, Chan AY, Chan PK, et al. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum. 2004;50(11):3619–25.
PubMed
Google Scholar